Orphan Drug Amendment
Executive Summary
Provision establishing U.S. disease incidence ceiling of 200,000 below which a drug treatment would be presumed an orphan, and thus eligible for tax credits under the law, is headed for White House following House and Senate passage during week ended Oct. 12. Amendment, part of Health Promotion and Disease Prevention Amendments of 1984 (S. 771), was agreed to by Sen. Hatch (R-Utah) and Rep. Waxman (D-Calif.) after Office of Management & Budget disagreed with FDA and the Treasury Dept. on the figure
You may also be interested in...
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.